Search results
Results from the WOW.Com Content Network
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Adult ADHD treatment Dr. Jeffrey Ditzzell, DO , a Manhattan-based psychiatrist who specializes in treating mood and anxiety disorders including ADHD says, "Medications can be an aspect of care ...
Cognitive disengagement syndrome (CDS) is a syndrome characterized by developmentally inappropriate, impairing, and persistent levels of decoupled attentional processing from the ongoing external context and resultant hypoactivity.
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
About six weeks ago, after my weekly pickleball league, I awoke to a stabbing pain in my right heel. I'd had knee pain, a jammed thumb, and other ouchies from my favorite sport, but never this ...
Males with ADHD, children, and adults exhibit higher rates of externalizing disorders or behaviors that manifest as aggressive, disruptive, rule-breaking behaviors, making them more likely to be referred for ADHD treatment. Adult males with ADHD are also more likely to display antisocial behaviors associated with antisocial personality disorder ...
Once spring and summer roll around and it’s time to switch to shorts, skirts and bathing suit bottoms, we know many become self-conscious about the appearance or their legs.
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.